Laser and immunotherapy combo takes on recurrent brain tumors
NCT ID NCT07620548
First seen Jun 11, 2026 · Last updated Jun 13, 2026 · Updated 1 time
Summary
This study tests a new approach for people with recurrent glioblastoma, an aggressive brain cancer. It combines a laser treatment that heats and destroys tumor tissue with an immunotherapy drug (cemiplimab) that helps the immune system fight cancer. The study compares this combination to standard chemotherapy, aiming to see if it can slow tumor growth and extend survival. About 99 participants will be randomly assigned to one of the two treatment groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic
Rochester, Minnesota, 55902, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.